Mohammed Qintar, MD
Interventional Cardiology · Lansing, MINPI 1649530445
Payments from drug & device makers
What this record shows
This record is dominated by grants: $21,000 of the $34,779 with a category attached, or 60.4%. Medtronic accounts for 65.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $23,930 and has fallen 95.5% since, to $1,068 in 2024.
Across 223 payments — averaging $155.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- Edwards Lifesciences$6K
- Abbott$2K
- Boston Scientific$919
- Angiodynamics, Inc.$579
- E.r. Squibb & Sons, L.L.C.$384
- plus $2K from 20 others
Across 15 payments — averaging $1612.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$24K
- Boston Scientific$583
What the payments were for
- Consulting fees$1,4754%
- Grants$21,00060%
- Travel & lodging$3,86611%
- Food & beverage$8,43724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $22,918 |
| Edwards Lifesciences | 66 | $6,028 |
| Abbott | 27 | $2,288 |
| Boston Scientific | 21 | $919 |
| Angiodynamics, Inc. | 5 | $579 |
| E.r. Squibb & Sons, L.L.C. | 20 | $384 |
| Shockwave Medical, Inc | 3 | $257 |
| Abiomed | 2 | $220 |
| Johnson & Johnson | 9 | $174 |
| Cardiva Medical, Inc. | 4 | $168 |
| Pfizer | 8 | $126 |
| Penumbra, Inc. | 1 | $92 |
| Inari Medical, Inc. | 3 | $91 |
| Teleflex LLC | 5 | $86 |
| Actelion Pharmaceuticals US, Inc. | 3 | $74 |
| Amgen | 4 | $69 |
| Terumo Medical Corporation | 1 | $69 |
| Novartis | 3 | $54 |
| Atricure, Inc. | 1 | $44 |
| Biosense Webster, Inc. | 1 | $34 |
| AstraZeneca | 2 | $28 |
| Imperative Care, Inc | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$1,444
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,387
- CoreValve Evolut$946
- AMPLATZER Occluders$875
- Xience V coronary stent system$470
- AngioVac$469
- COREVALVE EVOLUT R$291
- Edwards SAPIEN 3 Transcatheter Heart Valve$277
- MitraClip System$159
- AVVIGO Guidance System$150
- WATCHMAN Access System$137
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$133
- Impella$128
- EVOQUE$105
- GENERAL - THERAPIES$101
How this compares
$34,779 in reported general payments places this provider in the 80th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $35,225 |
| XareltoRivaroxaban | 17 | $15,628 |
| ClopidogrelClopidogrel Bisulfate | 33 | $520 |
| Metoprolol Succinate | 24 | $423 |
| Atorvastatin Calcium | 12 | $235 |
| Losartan Potassium | 25 | $138 |
| Carvedilol | 14 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $35,22540 claims |
| Johnson & JohnsonXarelto | $174 | $15,62817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Lansing
- Adnan KassierLansing$28K
- Maria MarkarianLansing$22K
- Nam ChoLansing$19K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.